BG61323B2 - Производни на пиперидина,тяхното получаване и използването им като лекарства - Google Patents

Производни на пиперидина,тяхното получаване и използването им като лекарства Download PDF

Info

Publication number: BG61323B2
Authority: BG; Bulgaria
Prior art keywords: hydrochloride; solution; paroxetine; crystalline; paroxetine hydrochloride
Prior art date: 1985-10-25

Application number

BG098345A

Other languages

Bulgarian (bg)

English (en)

Inventor

Roger Barnes

Marian Wood-Kaczmar

John Richardson

Ian Lynch

Philip Buxton

Original Assignee

Beecham Group P.L.C.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-25

Filing date

1993-12-29

Publication date

1997-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26289934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG61323(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-10-25 Priority claimed from GB858526408A external-priority patent/GB8526408D0/en

1985-10-25 Priority claimed from GB858526407A external-priority patent/GB8526407D0/en

1993-12-29 Application filed by Beecham Group P.L.C. filed Critical Beecham Group P.L.C.

1997-05-30 Publication of BG61323B2 publication Critical patent/BG61323B2/bg

Links

238000002360 preparation method Methods 0.000 title claims abstract description 13
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title description 13
229940126601 medicinal product Drugs 0.000 title 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims abstract description 51
229960005183 paroxetine hydrochloride Drugs 0.000 claims abstract description 17
239000003814 drug Substances 0.000 claims abstract description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 45
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 44
229960002296 paroxetine Drugs 0.000 claims description 36
238000000034 method Methods 0.000 claims description 18
150000001875 compounds Chemical class 0.000 claims description 16
239000012458 free base Substances 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 9
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 6
229910000041 hydrogen chloride Inorganic materials 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 4
230000006196 deacetylation Effects 0.000 claims description 4
238000003381 deacetylation reaction Methods 0.000 claims description 4
238000002844 melting Methods 0.000 claims description 3
230000008018 melting Effects 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 abstract description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 43
239000000243 solution Substances 0.000 description 34
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
239000000203 mixture Substances 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
239000002904 solvent Substances 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 9
239000013078 crystal Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
238000002425 crystallisation Methods 0.000 description 8
230000008025 crystallization Effects 0.000 description 8
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
239000007787 solid Substances 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 5
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
MWUISCCBFHLWLY-UHFFFAOYSA-N 1,2-dimethylpiperidine Chemical compound CC1CCCCN1C MWUISCCBFHLWLY-UHFFFAOYSA-N 0.000 description 4
ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
238000002329 infrared spectrum Methods 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
238000003756 stirring Methods 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 3
239000007789 gas Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
QDUXDCXILAPLAG-UHFFFAOYSA-N hydron;1-methylpiperidine;chloride Chemical compound Cl.CN1CCCCC1 QDUXDCXILAPLAG-UHFFFAOYSA-N 0.000 description 3
239000010410 layer Substances 0.000 description 3
-1 nitro, acetylamino, methylsulfonyl Chemical group 0.000 description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
RQBJOWKBGCDPOS-RVXRQPKJSA-N acetic acid;(3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical class CC(O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 RQBJOWKBGCDPOS-RVXRQPKJSA-N 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
159000000021 acetate salts Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
229910052925 anhydrite Inorganic materials 0.000 description 1
125000002102 aryl alkyloxo group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000010583 slow cooling Methods 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
125000004950 trifluoroalkyl group Chemical group 0.000 description 1
239000003021 water soluble solvent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

BG098345A 1985-10-25 1993-12-29 Производни на пиперидина,тяхното получаване и използването им като лекарства BG61323B2 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB858526408A GB8526408D0 (en)	1985-10-25	1985-10-25	Chemical process
GB858526407A GB8526407D0 (en)	1985-10-25	1985-10-25	Compounds

Publications (1)

Publication Number	Publication Date
BG61323B2 true BG61323B2 (bg)	1997-05-30

Family

ID=26289934

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG098345A BG61323B2 (bg)	1985-10-25	1993-12-29	Производни на пиперидина,тяхното получаване и използването им като лекарства

Country Status (18)

Country	Link
US (1)	US4721723A (fr)
EP (1)	EP0223403B1 (fr)
JP (1)	JPH0647587B2 (fr)
AU (1)	AU593295B2 (fr)
BG (1)	BG61323B2 (fr)
CA (1)	CA1287060C (fr)
CY (1)	CY1743A (fr)
CZ (1)	CZ391091A3 (fr)
DE (1)	DE3688827T2 (fr)
DK (1)	DK171694B1 (fr)
ES (1)	ES2058061T3 (fr)
FI (1)	FI87785C (fr)
HK (1)	HK125993A (fr)
IE (1)	IE59901B1 (fr)
NO (1)	NO171453C (fr)
NZ (1)	NZ218047A (fr)
PT (1)	PT83608B (fr)
SK (1)	SK391091A3 (fr)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK231088D0 (da) *	1988-04-28	1988-04-28	Ferrosan As	Piperidinforbindelser, deres fremstilling og anvendelse
IE66332B1 (en) *	1986-11-03	1995-12-27	Novo Nordisk As	Piperidine compounds and their preparation and use
DK58291D0 (da) *	1991-04-02	1991-04-02	Novo Nordisk As	Krystalinsk stof og dets fremstilling
GB9209687D0 (en) *	1992-05-06	1992-06-17	Smithkline Beecham Plc	Novel process
US5258517A (en) *	1992-08-06	1993-11-02	Sepracor, Inc.	Method of preparing optically pure precursors of paroxetine
US5276042A (en) *	1993-04-16	1994-01-04	Crenshaw Roger T	Treatment of premature ejaculation
EP0639568A1 (fr) *	1993-08-19	1995-02-22	Novo Nordisk A/S	Dérivés de pipéridine, leur préparation et leur utilisation dans le traitement des maladies neurodégénératives
GB9325644D0 (en) *	1993-12-15	1994-02-16	Smithkline Beecham Plc	Novel formulation
US20020086053A1 (en) *	1993-12-15	2002-07-04	Smithkline Beecham Plc	Formulations, tablets of paroxetine and process to prepare them
GB9402029D0 (en) *	1994-02-03	1994-03-30	Smithkline Beecham Plc	Novel formulation
ES2102295B1 (es) *	1994-03-18	1998-04-01	Ferrer Int	Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
ES2149726B1 (es) *	1995-02-06	2001-06-16	Smithkline Beecham Plc	Nuevos compuestos de paroxetina.
GB9502297D0 (en)	1995-02-06	1995-03-29	Smithkline Beecham Plc	Novel compound
US5856493A (en) *	1995-02-06	1999-01-05	Smithkline Beecham Corporation	Process for making novel form of paroxeting hydrochloride anhydrate
GB2297550B (en) *	1995-02-06	1997-04-09	Smithkline Beecham Plc	Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
AR001982A1 (es) *	1995-02-06	1998-01-07	Smithkline Beecham Plc	Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
US6548084B2 (en) *	1995-07-20	2003-04-15	Smithkline Beecham Plc	Controlled release compositions
GB9605828D0 (en) *	1996-03-20	1996-05-22	Smithkline Beecham Plc	Treatment method
CA2206592A1 (fr) *	1996-05-30	1997-11-30	Shu-Zhong Wang	Methode de preparation de chlorhydrate de paroxetine amorphe
JP3882224B2 (ja)	1996-05-31	2007-02-14	旭硝子株式会社	パロキセチンの製造方法
US5965555A (en) *	1996-06-07	1999-10-12	Hoechst Aktiengesellschaft	Xanthine compounds having terminally animated alkynol side chains
EP1394160A1 (fr) *	1996-06-13	2004-03-03	SUMIKA FINE CHEMICALS Co., Ltd.	Procédé pour la préparation de hydrochlorure cristallin de paroxetine
HU221921B1 (hu) *	1996-07-08	2003-02-28	Richter Gedeon Vegyészeti Gyár Rt.	N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
WO1998002556A2 (fr) *	1996-07-15	1998-01-22	Smithkline Beecham Plc	Criblage et utilisation d'esterase pour dedoublement stereospecifique
US6638948B1 (en) *	1996-09-09	2003-10-28	Pentech Pharmaceuticals, Inc.	Amorphous paroxetine composition
US5672612A (en) *	1996-09-09	1997-09-30	Pentech Pharmaceuticals, Inc.	Amorphous paroxetine composition
CA2193939C (fr) *	1996-12-24	2002-02-12	K.S. Keshava Murthy	Forme utile de chlorhydrate de paroxetine anhydre
SK283394B6 (sk)	1997-06-10	2003-07-01	Synthon B. V.	Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
US5955475A (en) *	1997-06-30	1999-09-21	Endo Pharmaceuticals Inc.	Process for manufacturing paroxetine solid dispersions
GB9726907D0 (en) *	1997-12-19	1998-02-18	Smithkline Beecham Plc	Novel compounds
SK11812000A3 (sk) *	1998-02-06	2001-08-06	Smithkline Beecham Plc	Soli paroxetínu, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
HUP0101215A3 (en) *	1998-03-16	2002-05-28	Smithkline Beecham Plc	Chrystalline form of paroxetine
AU2003200534B2 (en) *	1998-03-24	2004-12-02	Smithkline Beecham Plc	Paroxetine compositions
GB9806312D0 (en) *	1998-03-24	1998-05-20	Smithkline Beecham Plc	Novel formulations
US6699882B2 (en)	1998-03-24	2004-03-02	Smithkline Beecham P.L.C.	Paroxetine compositions
GB9808894D0 (en) *	1998-04-25	1998-06-24	Smithkline Beecham Plc	Novel compound
GB9808896D0 (en) *	1998-04-25	1998-06-24	Smithkline Beecham Plc	Novel compound
GB9812941D0 (en) *	1998-06-16	1998-08-12	Smithkline Beecham Plc	Method of treatment
US6300343B1 (en)	1998-06-16	2001-10-09	Smithkline Beecham Corporation	Method of treatment
CH689805A8 (fr) *	1998-07-02	2000-02-29	Smithkline Beecham Plc	Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9814316D0 (en) *	1998-07-02	1998-09-02	Smithkline Beecham Plc	Novel compounds
ES2138937B1 (es)	1998-07-07	2000-10-01	Medichem Sa	Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
CA2339857A1 (fr) *	1998-08-07	2000-02-17	Neal Ward	Procede de preparation d'une forme anhydre non cristalline d'hydrochlorure de paroxetine
EP1102764A1 (fr) *	1998-08-08	2001-05-30	Smithkline Beecham Plc	Sels de paroxetine
GB9824298D0 (en) *	1998-11-05	1998-12-30	Smithkline Beecham Plc	Novel process
GB9826176D0 (en) *	1998-11-28	1999-01-20	Smithkline Beecham Plc	Novel process
GB9826175D0 (en) *	1998-11-28	1999-01-20	Smithkline Beecham Plc	Novel process
GB9826178D0 (en) *	1998-11-30	1999-01-20	Smithkline Beecham Plc	Novel process
GB9826180D0 (en) *	1998-11-30	1999-01-20	Smithkline Beecham Plc	Novel process
GB9826242D0 (en) *	1998-11-30	1999-01-20	Smithkline Beecham Plc	Novel process
EP1408039A3 (fr) *	1998-11-30	2004-05-12	Smithkline Beecham Plc	Solvates mixtes de propan-2-ol et de paroxetine
GB9826171D0 (en) *	1998-11-30	1999-01-20	Smithkline Beecham Plc	Novel compounds
GB9827387D0 (en) *	1998-12-11	1999-02-03	Smithkline Beecham Plc	Novel process
GB9828780D0 (en) *	1998-12-29	1999-02-17	Smithkline Beecham Plc	Novel process
GB9828767D0 (en) *	1998-12-29	1999-02-17	Smithkline Beecham Plc	Novel process
GB9828781D0 (en) *	1998-12-29	1999-02-17	Smithkline Beecham Plc	Novel process
GB9828779D0 (en) *	1998-12-29	1999-02-17	Smithkline Beecham Plc	Novel process
JP4854115B2 (ja) *	1999-03-12	2012-01-18	エイシカファーマシューティカルスリミテッド	無水パロキセチン用安定製剤形
FR2791345B1 (fr) *	1999-03-26	2001-05-04	Adir	Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6245782B1 (en)	1999-05-17	2001-06-12	Heartdrug Research L.L.C.	Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
GB9914585D0 (en) *	1999-06-22	1999-08-25	Smithkline Beecham Plc	Novel process
GB9914583D0 (en) *	1999-06-22	1999-08-25	Smithkline Beecham Plc	Novel process
KR100759159B1 (ko)	1999-07-01	2007-09-14	이탈파마코 에스.피.에이.	파록세틴과 사이클로덱스트린 또는 사이클로덱스트린유도체의 컴플렉스
GB9916187D0 (en) *	1999-07-09	1999-09-08	Smithkline Beecham Plc	Novel process
GB9919052D0 (en) *	1999-08-12	1999-10-13	Smithkline Beecham Plc	Novel compound composition and process
GB9923446D0 (en) *	1999-10-04	1999-12-08	Smithkline Beecham Plc	Novel process
US6503927B1 (en)	1999-10-28	2003-01-07	Pentech Pharmaceuticals, Inc.	Amorphous paroxetine composition
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
HU226912B1 (en) *	2000-04-07	2010-03-01	Richter Gedeon Nyrt	New paroxetin salt and medicament containing it
JP2003530437A (ja) *	2000-04-13	2003-10-14	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	Ａβ４２低下物質
US6660298B1 (en) *	2000-07-27	2003-12-09	Pentech Pharmaceuticals, Inc.	Paroxetine tablets and capsules
US20030109577A1 (en) *	2000-10-27	2003-06-12	Ken Liljegren	Pharmaceutical composition containing citalopram
DE20100529U1 (de) *	2001-01-11	2001-05-10	Synthon Bv	Pharmazeutische Tablette umfassend Paroxetinmesylat
US6610326B2 (en) *	2001-02-16	2003-08-26	Andrx Corporation	Divalproex sodium tablets
US6720003B2 (en) *	2001-02-16	2004-04-13	Andrx Corporation	Serotonin reuptake inhibitor formulations
NL1017421C2 (nl)	2001-02-21	2002-01-15	Synthon Bv	Werkwijze voor het vervaardigen van paroxetine.
US6645946B1 (en)	2001-03-27	2003-11-11	Pro-Pharmaceuticals, Inc.	Delivery of a therapeutic agent in a formulation for reduced toxicity
AU2002318185A1 (en) *	2001-06-13	2002-12-23	Teva Pharmaceutical Industries Ltd.	Process for the preparation of paroxetine substantially free of alkoxy impurities
IL159280A0 (en) *	2001-06-14	2004-06-01	Teva Pharma	A process for preparing paroxetine hcl which limits formation of pink colored compounds
IL159326A0 (en)	2001-07-31	2004-06-01	Lundbeck & Co As H	Crystalline composition containing escitalopram
CA2456233A1 (fr) *	2001-08-02	2003-03-13	Spurcourt Limited	Sel d'isethionate de paroxetine, procede de preparation et utilisation dans le traitement de la depression
EP1414408B1 (fr) *	2001-08-09	2006-03-29	Smithkline Beecham Plc	Composition comprenant de la paroxetine et un sel de glycyrrhizinate pharmaceutiquement acceptable
NZ532432A (en) *	2001-10-22	2005-02-25	Synthon Bv	N-formyl paroxetine compounds and their use in a synthetic route for obtaining paroxetine
WO2003057150A2 (fr) *	2001-12-28	2003-07-17	Teva Pharmaceutical Industries Ltd.	Formulation pharmaceutique d'hydrochlorure stable et procédé de préparation
WO2003072104A1 (fr) *	2002-02-22	2003-09-04	Teva Pharmaceutical Industries Ltd.	Preparation de paroxetine impliquant de nouveaux intermediaires
EP2316468A1 (fr)	2002-02-22	2011-05-04	Shire LLC	Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US6956121B2 (en) *	2002-03-01	2005-10-18	Teva Pharmaceutical Industries Ltd.	Preparation of paroxetine involving novel intermediates
UA77536C2 (en) *	2002-07-03	2006-12-15	Lundbeck & Co As H	Secondary aminoaniline piperidines as mch1 antagonists and their use
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003271056B2 (en) *	2002-09-19	2009-01-08	Sumitomo Chemical Company, Limited	Process for producing paroxetine hydrochloride hydrate
WO2004026860A1 (fr) *	2002-09-19	2004-04-01	Sumitomo Chemical Company, Limited	Procedes de precipitation cristalline
US20040220153A1 (en) *	2002-09-24	2004-11-04	Jost-Price Edward Roydon	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004071431A2 (fr) *	2003-02-05	2004-08-26	Myriad Genetics, Inc.	Composition et methode de traitement de troubles neurodegeneratifs
ATE352305T1 (de) *	2003-03-12	2007-02-15	Teva Pharma	Stabile pharmazeutische zusammensetzungen mit desloratadine
US20060135547A1 (en) *	2003-03-12	2006-06-22	Toth Zoltan G	Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
KR20060040676A (ko) *	2003-07-11	2006-05-10	미리어드 제네틱스, 인크.	알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
PL1691811T3 (pl)	2003-12-11	2014-12-31	Sunovion Pharmaceuticals Inc	Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20050154020A1 (en) *	2004-01-14	2005-07-14	Synaptic Pharmaceutical Corporation	4-Aryl piperidines
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006001877A2 (fr) *	2004-04-13	2006-01-05	Myriad Genetics, Inc.	Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
EP1737473A4 (fr) *	2004-04-19	2009-08-26	Noven Therapeutics Llc	Combinaisons de lithium et utilisations associees
AU2005241023A1 (en) *	2004-04-29	2005-11-17	Keystone Retaining Wall Systems, Inc.	Veneers for walls, retaining walls and the like
US20050266082A1 (en) *	2004-05-26	2005-12-01	Patel Satishkumar A	Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006020852A2 (fr) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020850A2 (fr) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
BRPI0514303A (pt) *	2004-08-11	2008-06-10	Myriad Genetics Inc	composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006018318A1 (fr) *	2004-08-18	2006-02-23	Synthon B.V.	Compositions liquides de paroxetine
WO2006023347A1 (fr) *	2004-08-20	2006-03-02	Alpharma, Inc.	Formulations à base de paroxétine
KR100672184B1 (ko) *	2004-09-21	2007-01-19	주식회사종근당	파록세틴의 콜린산 또는 콜린산 유도체 염
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004056398A1 (de) *	2004-11-23	2006-05-24	Bayer Materialscience Ag	Hydrolysestabile, hydrophobe, lösemittelfreie Polyole
US20060216345A1 (en) *	2005-03-24	2006-09-28	Sun Pharmaceutical Industries Limited	Oral pharmaceutical composition including paroxetine
ATE407933T1 (de) *	2005-05-26	2008-09-15	Apotecnia S A	Verfahren zur herstellung von paroxetin hydrochlorid hemihydrat
US20070015832A1 (en) *	2005-07-14	2007-01-18	Myriad Genetics, Incorporated	Methods of treating overactive bladder and urinary incontinence
CA2615063A1 (fr) *	2005-07-22	2007-02-01	Myriad Genetics, Inc.	Formes posologiques et preparations a charge medicamenteuse elevee
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112031A1 (en) *	2005-11-14	2007-05-17	Gant Thomas G	Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
KR100591142B1 (ko) *	2005-11-04	2006-06-20	지엘팜텍 주식회사	파록세틴을 활성물질로 함유하는 장용성 서방형 정제
WO2007054978A2 (fr) *	2005-11-10	2007-05-18	Jubilant Organosys Limited	Procede de preparation de semi-hydrate de chlorhydrate de paroxetine
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
EP2540725A1 (fr)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphes de 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
WO2008006099A2 (fr) *	2006-07-07	2008-01-10	Myriad Genetics, Inc.	Traitement de troubles psychiatriques
WO2008012623A1 (fr) *	2006-07-25	2008-01-31	Pfizer Products Inc.	Composés de benzimidazolyle constituant des potentialisateurs du sous-type de récepteur de glutamate mglur2
US20080033050A1 (en)	2006-08-04	2008-02-07	Richards Patricia Allison Tewe	Method of treating thermoregulatory disfunction with paroxetine
PT2118074E (pt)	2007-02-01	2014-03-20	Resverlogix Corp	Compostos para a prevenção e tratamento de doenças cardiovasculares
US20080300258A1 (en) *	2007-05-30	2008-12-04	Souza Fabio Eduardo Silva	Anhydrous ciprofloxacin hydrochloride
US9138430B2 (en) *	2007-12-27	2015-09-22	Mylan Specialty L.P.	Formulation and method for the release of paroxetine in the large intestine
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
DE102009030506A1 (de) *	2008-06-30	2009-12-31	Borgwarner Inc., Auburn Hills	Reibungsmaterialien
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR101913109B1 (ko)	2009-03-18	2018-10-31	리스버로직스 코퍼레이션	신규한 소염제
JP2010260826A (ja) *	2009-05-08	2010-11-18	Sumitomo Chemical Co Ltd	パロキセチン塩酸塩半水和物の製造方法
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
JP5700367B2 (ja) *	2010-05-06	2015-04-15	高田製薬株式会社	パロキセチン含有フイルムコ−テイング経口製剤
WO2011161161A1 (fr)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Thérapie du diabète
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
KR20140045925A (ko)	2011-03-17	2014-04-17	루핀 리미티드	선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
GB201108345D0 (en) *	2011-05-18	2011-06-29	Aesica Pharmaceuticals Ltd	Process
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
CN102285973B (zh) *	2011-09-20	2013-03-06	海南美大制药有限公司	一种盐酸帕罗西汀化合物及其制法
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
AU2013204159B2 (en) *	2013-03-15	2015-05-07	Bionomics Limited	A Crystalline Form of an Anxiolytic Compound
EP3110449B1 (fr)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Utilisation médicale d'un inhibiteur de dpp-4
CN104447714A (zh) *	2014-11-18	2015-03-25	成都医路康医学技术服务有限公司	一种盐酸帕罗西汀的生产工艺
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1422263A (en) *	1973-01-30	1976-01-21	Ferrosan As	4-phenyl-piperidine compounds
EP0190496A3 (fr) *	1984-12-13	1987-05-27	Beecham Group Plc	Dérivés de la pipéridine à activité gastro-intestinale

1986
- 1986-10-14 EP EP86307919A patent/EP0223403B1/fr not_active Expired - Lifetime
- 1986-10-14 ES ES86307919T patent/ES2058061T3/es not_active Expired - Lifetime
- 1986-10-14 DE DE86307919T patent/DE3688827T2/de not_active Expired - Lifetime
- 1986-10-23 US US06/922,530 patent/US4721723A/en not_active Expired - Lifetime
- 1986-10-23 NZ NZ218047A patent/NZ218047A/xx unknown
- 1986-10-23 NO NO864237A patent/NO171453C/no unknown
- 1986-10-23 PT PT83608A patent/PT83608B/pt unknown
- 1986-10-23 CA CA000521223A patent/CA1287060C/fr not_active Expired - Lifetime
- 1986-10-23 AU AU64332/86A patent/AU593295B2/en not_active Expired
- 1986-10-23 DK DK508786A patent/DK171694B1/da not_active IP Right Cessation
- 1986-10-23 IE IE280286A patent/IE59901B1/en not_active IP Right Cessation
- 1986-10-24 JP JP61253499A patent/JPH0647587B2/ja not_active Expired - Lifetime
- 1986-10-24 FI FI864320A patent/FI87785C/fi not_active IP Right Cessation
1991
- 1991-12-19 SK SK3910-91A patent/SK391091A3/sk unknown
- 1991-12-19 CZ CS913910A patent/CZ391091A3/cs unknown
1993
- 1993-11-11 HK HK1259/93A patent/HK125993A/en not_active IP Right Cessation
- 1993-12-29 BG BG098345A patent/BG61323B2/bg unknown
1995
- 1995-02-17 CY CY174395A patent/CY1743A/xx unknown

Also Published As

Publication number	Publication date
JPS62129280A (ja)	1987-06-11
PT83608A (en)	1986-11-01
DE3688827D1 (de)	1993-09-09
NO864237D0 (no)	1986-10-23
IE862802L (en)	1987-04-25
HK125993A (en)	1993-11-19
NO171453C (no)	1993-03-17
AU593295B2 (en)	1990-02-08
FI864320A0 (fi)	1986-10-24
DK171694B1 (da)	1997-03-17
FI87785C (fi)	1993-02-25
NO171453B (no)	1992-12-07
NZ218047A (en)	1989-03-29
NO864237L (no)	1987-04-27
ES2058061T3 (es)	1994-11-01
SK391091A3 (en)	2000-10-09
US4721723A (en)	1988-01-26
EP0223403A2 (fr)	1987-05-27
EP0223403B1 (fr)	1993-08-04
DK508786D0 (da)	1986-10-23
EP0223403A3 (en)	1989-09-06
FI87785B (fi)	1992-11-13
CA1287060C (fr)	1991-07-30
CZ391091A3 (en)	1994-01-19
JPH0647587B2 (ja)	1994-06-22
AU6433286A (en)	1987-04-30
IE59901B1 (en)	1994-04-20
DE3688827T2 (de)	1994-03-31
PT83608B (pt)	1989-05-31
CY1743A (en)	1995-02-17
DK508786A (da)	1987-04-26
FI864320L (fi)	1987-04-26

Publication	Publication Date	Title
BG61323B2 (bg)	1997-05-30	Производни на пиперидина,тяхното получаване и използването им като лекарства
HUP0003141A2 (en)	2001-03-28	4-phenylpiperidine derivatives, process for producing them and pharmaceutical compositions containing them
US5354760A (en)	1994-10-11	Crystalline Tiagabine monohydrate, its preparation and use
PT970955E (pt)	2000-11-30	Metanossulfonato de paroxetina
KR20030081458A (ko)	2003-10-17	비-수화 펙소페나딘 염화수소의 제조방법 및 이 방법에의하여 얻어지는 신규 결정 형태
WO2002053135A1 (fr)	2002-07-11	Base libre d'amlodipine
CA2164296C (fr)	2007-01-23	Chimie heterocyclique
WO2002102777A2 (fr)	2002-12-27	Nouvelles formes cristallines d'acide 4-[4-[4-(hydroxydiphenylmethyl)-1-piperindinyl]-1-hydroxybutyl]-$g(a)-$g(a)- dimethylbenzene acetique et son chlorhydrate
AU2001278094A1 (en)	2003-05-15	Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride
JP2005350459A (ja)	2005-12-22	フェキソフェナジンの多形体およびその製造方法
US7335380B2 (en)	2008-02-26	Amlodipine free base
WO2005023769A1 (fr)	2005-03-17	Procede pour l'elaboration de sels d'amlodipine
EP2072510A1 (fr)	2009-06-24	Forme cristalline d'azélastine
DK175352B1 (da)	2004-09-06	Fremgangsmåde til fremstilling af 4-phenylpiperidinderivater
BE1014922A3 (nl)	2004-06-01	Amlodipine als vrije base.
NL1019882C2 (nl)	2003-08-04	Amlodipine vrije base.
BG104973A (bg)	2001-09-28	Пароксетин 10-камфорсулфонат за лечение на cns заболявания
GB2385268A (en)	2003-08-20	Amlodipine free base
SI21121A (sl)	2003-08-31	Prosta baza amlodipina
CZ20002845A3 (cs)	2001-01-17	Soli paroxetinu